東誠藥業(002675.SZ):就引進韓國DCB公司用於檢測疑似帕金森病患者PET成像診斷藥物的事項達成協議
格隆匯12月27日丨東誠藥業(002675.SZ)公佈,2018年12月20日,公司披露了《關於簽署框架合作協議的公告》。框架協議簽署後,經過公司與DuChemBio Co., Ltd.(“DCB”)的溝通協商,就引進韓國DCB公司用於檢測疑似帕金森病患者PET成像診斷藥物的事項達成協議,並於2019年12月27日,正式簽訂了《排他許可和開發協議》,公司將獲得該產品在中國的臨牀開發、生產和市場銷售的獨家權利。
DCB(許可方)是韓國的一家註冊企業,主要研發方向為腫瘤學和神經學的新型PET放射性藥物,經過多年積累,在開發、註冊、製造和商業化方面擁有豐富的經驗。其成功開發並商業化N-(3-[18F]氟丙基)-2β-甲酯基-3β-(4-碘苯基)去甲基託烷(“FP-CIT”),該產品用於疑似帕金森病患者PET成像診斷。
公司通過與韓國DCB的技術合作,獲取其在帕金森病相關藥物開發方面的研發優勢,引進對方產品在中國的臨牀開發、生產和市場銷售權益,對公司短期經營業績不會構成重大影響,但長期來看有助於公司增加核素藥物產品的經營種類,豐富產品管線,拓寬收入和利潤來源,符合公司戰略發展的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.